Theratechnologies Inc T.TH

Sec filing for 150000000$ Shelf Offering

[palinc2000]

Intetedting

[palinc2000]

st and pancreatic cancers.  The Corporation’s Phase 1 study evaluating its novel investigational proprietary PDC TH1902 for the treatment of sortilin-positive cancers is progressing as planned. To date, the study has dosed several patients with tumors for which no known effective therapies exist, with some receiving more docetaxel, when conjugated to TH1902, than the indicated dose of

[palinc2000]

1 clinical trial.  The Corporation has reduced the time spent on preclinical work on TH1904, its second PDC derived from its SORT1+ TechnologyTM, and has begun working on other PDCs, primarily to advance a PDC using SN38

[palinc2000]

es qualified by this Prospectus.  The conduct of the Phase 3 clinical trial evaluating tesamorelin for the treatment of NASH in the general population will be costly and the Corporation has decided to secure additional resources, including finding a partner, prior to initiating such clinical trial, all of which will result in a postponement of the initiation of such trial. Although the

[qwerty22]

And this is the wording in the atm. So this is in addition to ATM?

[palinc2000]

Thx for comparing the wording I must admit that I did not see that coming at least not during  this week, Legally I think this is in addition to the ATM but I may be wrong

[SPCEO1]

I beleieve this is just a required update to the original shelf offering's prospectus and it is in addition to the ATM, just as the shelf and ATM have co-existed already. So, they have different ways they could go with financing should the choose to do so, a decision that will be driven by the phase 1a results and the board's willingness to risk it in NASH when no other partner appears to

[qwerty22]

With ADCs getting approved with SN38 it may just be they think it offers something better than Doxorubicin. It's fine that Dox was used as a test system in the R&D phase and never goes to IND and the clinic. I do think SN38 brings something a little different to the platform given it's a much more toxic molecule that can't be used in a 'naked' form. I don't think it

[palinc2000]

POsted a month ago

[qwerty22]

That's essentially the same wording as the quarterly report.

[palinc2000]

I did not compare the wording in the 2 reports ,,Just copied pasted as I was reading